Arcinova Releases Latest Case Study
The challenge - to develop stable sterile formulations of a drug substance for intravenous administration in phase I clinical trials. The drug substance, intended for the treatment of CNS (Central Nervous System) related disorders, was physically and chemically unstable in aqueous media and there was a requirement for the product to be delivered both as a bolus and maintenance dose over an extended period of several days.
Find out more about how we solved the issue here
Discover how Arcinova can help
We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.